CN111447921B - 烟碱片剂 - Google Patents

烟碱片剂 Download PDF

Info

Publication number
CN111447921B
CN111447921B CN201880078877.9A CN201880078877A CN111447921B CN 111447921 B CN111447921 B CN 111447921B CN 201880078877 A CN201880078877 A CN 201880078877A CN 111447921 B CN111447921 B CN 111447921B
Authority
CN
China
Prior art keywords
nicotine
tablet
seconds
oral administration
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880078877.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111447921A (zh
Inventor
布鲁诺·普罗夫斯特高·涅尔森
肯特·阿尔宾·涅尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fertin Pharma AS
Original Assignee
Fertin Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64744343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111447921(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fertin Pharma AS filed Critical Fertin Pharma AS
Publication of CN111447921A publication Critical patent/CN111447921A/zh
Application granted granted Critical
Publication of CN111447921B publication Critical patent/CN111447921B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880078877.9A 2017-12-08 2018-12-07 烟碱片剂 Active CN111447921B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201770925 2017-12-08
DKPA201770925 2017-12-08
PCT/DK2018/050335 WO2019110072A1 (en) 2017-12-08 2018-12-07 Nicotine tablet

Publications (2)

Publication Number Publication Date
CN111447921A CN111447921A (zh) 2020-07-24
CN111447921B true CN111447921B (zh) 2023-10-13

Family

ID=64744343

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880078877.9A Active CN111447921B (zh) 2017-12-08 2018-12-07 烟碱片剂

Country Status (10)

Country Link
US (3) US11738016B2 (enExample)
EP (2) EP3720418B1 (enExample)
JP (1) JP7278281B2 (enExample)
CN (1) CN111447921B (enExample)
AU (1) AU2018378648B2 (enExample)
CA (1) CA3085062C (enExample)
DK (1) DK3720418T3 (enExample)
ES (1) ES2890975T3 (enExample)
PL (1) PL3720418T3 (enExample)
WO (1) WO2019110072A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018378648B2 (en) 2017-12-08 2021-06-03 Fertin Pharma A/S Nicotine tablet
EP3720497A1 (en) 2017-12-08 2020-10-14 Fertin Pharma A/S High nicotine concentration
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US12439952B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Moist oral compositions
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US12439949B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Oral compositions with reduced water activity
CA3181912A1 (en) 2020-06-08 2021-12-16 Anthony Richard Gerardi Effervescent oral composition comprising an active ingredient
US11382861B1 (en) * 2020-12-17 2022-07-12 Nirajkumar Karneshbhai Patel Nicotine pouch
CA3223902A1 (en) 2021-06-25 2022-12-29 Richard Svensson Oral products and method of manufacture
JP2024530905A (ja) 2021-07-30 2024-08-27 ニコベンチャーズ トレーディング リミテッド 微結晶性セルロースを含むエアロゾル生成基材
CN113827575A (zh) * 2021-11-02 2021-12-24 上海普康药业有限公司 一种利伐沙班片剂及其制备方法
CN115969898A (zh) * 2023-02-09 2023-04-18 东莞市吉纯生物技术有限公司 一种防治口腔溃疡的口含烟含片及其制备方法
US20250082579A1 (en) 2023-09-12 2025-03-13 Fertin Pharma A/S Orally disintegrating nicotine tablet for use under lip
EP4543417A1 (en) 2023-09-12 2025-04-30 Fertin Pharma A/S Orally disintegrating nicotine tablet for use under lip

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101472591A (zh) * 2006-05-16 2009-07-01 麦克内尔股份公司 口腔内递送包含氨基丁三醇作为缓冲剂的烟碱的包衣药物
CN101484188A (zh) * 2006-05-16 2009-07-15 麦克内尔股份公司 口腔内递送包含氨基丁三醇作为缓冲剂的烟碱的药物产品
WO2009134947A1 (en) * 2008-05-01 2009-11-05 Smithkline Beecham Corporation Nicotine lozenge compositions
WO2010044736A1 (en) * 2008-10-14 2010-04-22 Mcneil Ab Multi portion intra-oral dosage form and use thereof
CN101795710A (zh) * 2007-05-16 2010-08-04 麦克内尔股份公司 用氨基酸缓冲的口服尼古丁制剂

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866046A (en) 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5549906A (en) 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5810018A (en) * 1994-12-29 1998-09-22 Monte; Woodrow C. Method, composition and apparatus for reducing the incidence of cigarette smoking
WO2000024380A1 (en) 1998-10-27 2000-05-04 Fuisz Technologies Ltd. Microparticles containing peg and/or peg glyceryl esters
US20010016593A1 (en) 1999-04-14 2001-08-23 Wilhelmsen Paul C. Element giving rapid release of nicotine for transmucosal administration
US6583160B2 (en) 1999-04-14 2003-06-24 Steve Smith Nicotine therapy method and oral carrier for assuaging tobacco-addiction
US6248760B1 (en) 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
US6544552B2 (en) 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
DE60232496D1 (de) * 2001-03-06 2009-07-16 Kyowa Hakko Kirin Co Ltd Tabletten, die in der mundhöhle schnell zerfallen
NZ530439A (en) 2001-04-20 2004-11-26 Lavipharm Lab Inc Intraoral delivery of nicotine for smoking cessation
US20060057207A1 (en) 2001-11-30 2006-03-16 Pfizer Inc Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
SE0104388D0 (sv) 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
US8992974B2 (en) 2003-02-24 2015-03-31 Pharmaceuticals Productions, Inc. Transmucosal drug delivery system
US20150080442A1 (en) * 2003-02-24 2015-03-19 Pharmaceutical Productions Inc. Transmucosal drug delivery system
TW200514579A (en) 2003-07-24 2005-05-01 Smithkline Beecham Corp Orally dissolving films
US7387788B1 (en) * 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
WO2005055945A2 (en) * 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
US20070196474A1 (en) 2004-04-30 2007-08-23 Withiam Michael C Rapidly disintegrating low friability tablets comprising calcium carbonate
ES2403167T3 (es) 2005-12-21 2013-05-14 Basf Se Polivinilpirrolidona entrelazada finamente dividida como agente desintegrador de tabletas
US10092715B2 (en) 2006-09-27 2018-10-09 Niconovum Usa, Inc. Directional use
AU2007328373A1 (en) * 2006-12-01 2008-06-12 Cima Labs Inc. Oral transmucosal nicotine dosage form
US20080286341A1 (en) 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
WO2009007771A1 (en) 2007-07-06 2009-01-15 Gumlink A/S High volume compressed chewing gum tablet
SI2177213T1 (sl) 2008-09-17 2013-03-29 Siegfried Ltd. Nikotin vsebujoč granulat
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
JP6521564B2 (ja) 2010-12-22 2019-05-29 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 速崩性の固体被覆剤形
SE535587C2 (sv) 2011-03-29 2012-10-02 Chill Of Sweden Ab Produkt innehållande ett fritt nikotinsalt och en ej vattenlöslig påse
TW201318650A (zh) 2011-11-02 2013-05-16 Hua Yu Wuxi Pharmaceutical Co Ltd 口崩片組成物
US20140328973A1 (en) 2011-12-22 2014-11-06 Bruno Provstgaard Nielsen Method of releasing nicotine from chewing gum
US20130177646A1 (en) * 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
US11779045B2 (en) * 2013-10-03 2023-10-10 Altria Client Services Llc Dissolvable-chewable exhausted-tobacco tablet
CN106659696B (zh) 2014-07-08 2021-08-20 费尔廷制药公司 包含两个隔室的经口递送系统
US20170172995A1 (en) 2015-09-08 2017-06-22 Venkateswara Rao Repaka Pharmaceutical compositions of Nicotine and process for preparation thereof
US20170165252A1 (en) 2015-12-10 2017-06-15 Niconovum Usa Inc. Protein-enriched therapeutic composition
AU2016381372B2 (en) 2015-12-30 2021-07-22 Next Generation Labs, LLC Nicotine replacement therapy products comprising synthetic nicotine
WO2019110073A1 (en) 2017-12-08 2019-06-13 Fertin Pharma A/S Solid oral nicotine formulation
EP3720499A1 (en) 2017-12-08 2020-10-14 Fertin Pharma A/S Nicotine mouth spray
EP3720497A1 (en) 2017-12-08 2020-10-14 Fertin Pharma A/S High nicotine concentration
AU2018378648B2 (en) 2017-12-08 2021-06-03 Fertin Pharma A/S Nicotine tablet
EP3720498A1 (en) 2017-12-08 2020-10-14 Fertin Pharma A/S High nicotine absorption

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101472591A (zh) * 2006-05-16 2009-07-01 麦克内尔股份公司 口腔内递送包含氨基丁三醇作为缓冲剂的烟碱的包衣药物
CN101484188A (zh) * 2006-05-16 2009-07-15 麦克内尔股份公司 口腔内递送包含氨基丁三醇作为缓冲剂的烟碱的药物产品
CN101795710A (zh) * 2007-05-16 2010-08-04 麦克内尔股份公司 用氨基酸缓冲的口服尼古丁制剂
WO2009134947A1 (en) * 2008-05-01 2009-11-05 Smithkline Beecham Corporation Nicotine lozenge compositions
WO2010044736A1 (en) * 2008-10-14 2010-04-22 Mcneil Ab Multi portion intra-oral dosage form and use thereof
CN102186461A (zh) * 2008-10-14 2011-09-14 麦克内尔股份公司 多部分口腔内剂型及其用途

Also Published As

Publication number Publication date
EP3720418B1 (en) 2021-08-04
WO2019110072A1 (en) 2019-06-13
US12433881B2 (en) 2025-10-07
US20240285610A1 (en) 2024-08-29
CA3085062A1 (en) 2019-06-13
JP2021505546A (ja) 2021-02-18
US11738016B2 (en) 2023-08-29
JP7278281B2 (ja) 2023-05-19
PL3720418T3 (pl) 2021-12-20
CA3085062C (en) 2022-08-16
ES2890975T3 (es) 2022-01-25
US20190175581A1 (en) 2019-06-13
AU2018378648B2 (en) 2021-06-03
EP3720418A1 (en) 2020-10-14
US20230346768A1 (en) 2023-11-02
EP3906916A1 (en) 2021-11-10
US12005058B2 (en) 2024-06-11
CN111447921A (zh) 2020-07-24
DK3720418T3 (da) 2021-10-11
AU2018378648A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
CN111447921B (zh) 烟碱片剂
CN111432840B (zh) 固体经口烟碱制剂
JP7574286B2 (ja) 圧縮ニコチンロゼンジ
EP3720498A1 (en) High nicotine absorption
US20230158011A1 (en) High nicotine concentration
RU2786451C2 (ru) Твердый пероральный никотиновый состав
RU2831119C2 (ru) Твердый пероральный никотиновый состав
US20250082579A1 (en) Orally disintegrating nicotine tablet for use under lip
RU2825844C1 (ru) Прессованная никотиновая пастилка
US20250082569A1 (en) Orally disintegrating nicotine tablet with low amount of flavor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant